中国献血浆者和全血献血者中甲肝病毒和B19细小病毒的流行情况。

The prevalence of hepatitis A virus and parvovirus B19 in source-plasma donors and whole blood donors in China.

作者信息

Han T, Li C, Zhang Y, Wang Y, Wu B, Ke L, Liu G, Li L, Liu Y, Liu Z

机构信息

School of Public Health, Anhui Medical University, Hefei, China.

Experimental Center of Transfusion Medicine, Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Chengdu, China.

出版信息

Transfus Med. 2015 Dec;25(6):406-10. doi: 10.1111/tme.12259. Epub 2015 Nov 13.

DOI:10.1111/tme.12259

PMID:26564017

Abstract

AIMS

To compare the prevalence of hepatitis A virus (HAV) and human parvovirus B19 (B19V) between source-plasma (SP) donors and whole blood (WB) donors.

BACKGROUND

In China, source plasma is in severe shortage while plasma recovered from WB is in surplus. Thus, the government is considering transferring the recovered plasma (RP) to produce plasma derivatives. HAV and B19V are two pathogens threatening the safety of plasma-based derivatives. However, there is no data about if transferring of the RP to produce plasma derivatives will increase the risk of HAV and B19V infection. Thus, we compared the prevalence of HAV and B19V between SP donors and WB donors in this study.

METHODS

A total of 5030 samples from SP donors and 5040 samples from WB donors were collected. All the samples were tested for HAV RNA and B19V DNA and tested for HAV IgM by enzyme-linked immunosorbent assay (ELISA).

RESULTS

The prevalence of B19V DNA was 0.06% (95% confidence interval (CI), 0-0.09%) in WB donors and 0.079% (95% CI, 0-0.12%) in SP donors, respectively. No significant difference was found in the prevalence of B19V DNA between SP donors and WB donors. The prevalence of anti-HAV IgM in SP donors was 0.079% whereas no WB donor sample was found anti-HAV IgM reactive.

CONCLUSIONS

The transfer of RP to producing plasma derivatives will not increase the risk of transmission of HAV and B19 through plasma products.

摘要

目的

比较单采血浆（SP）捐献者和全血（WB）捐献者中甲型肝炎病毒（HAV）和人细小病毒B19（B19V）的流行率。

背景

在中国，单采血浆严重短缺，而从全血中回收的血浆过剩。因此，政府正在考虑将回收血浆（RP）用于生产血浆衍生物。HAV和B19V是两种威胁血浆衍生物安全性的病原体。然而，尚无关于将RP用于生产血浆衍生物是否会增加HAV和B19V感染风险的数据。因此，我们在本研究中比较了SP捐献者和WB捐献者中HAV和B19V的流行率。

方法

共采集了5030份来自SP捐献者的样本和5040份来自WB捐献者的样本。所有样本均检测HAV RNA和B19V DNA，并通过酶联免疫吸附测定（ELISA）检测HAV IgM。

结果

B19V DNA在WB捐献者中的流行率为0.06%（95%置信区间（CI），0 - 0.09%），在SP捐献者中的流行率为0.079%（95%CI，0 - 0.12%）。SP捐献者和WB捐献者之间B19V DNA的流行率无显著差异。SP捐献者中抗HAV IgM的流行率为0.079%，而未发现WB捐献者样本有抗HAV IgM反应性。